Stock PER PERCHERON THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Percheron Therapeutics Limited

Equities

PER

AU0000317281

End-of-day quote Australian S.E.
Other stock markets
 23:00:00 12/05/2024 BST 		5-day change 1st Jan Change
0.075 AUD 0.00% Intraday chart for Percheron Therapeutics Limited -2.60% +27.12%
05-06 WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102 MT
02-28 Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dimerix Appoints Nonexecutive Chair
MT
Antisense Therapeutics Limited has Changed its Name to Percheron Therapeutics Limited
CI
Antisense Therapeutics Appoints CEO/Managing Director
MT
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023
CI
Antisense Therapeutics Limited Announces Management Changes
CI
Antisense Therapeutics Appoints CEO/Managing Director
MT
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023
CI
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director
CI
Patrys Names Chairman
MT
Antisense Therapeutics' CEO to Retire
MT
Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer
CI
Antisense Therapeutics Limited Announces Retirement of Gary Pace as Non-Executive Director
CI
Antisense Therapeutics Appoints Commercial Chief
MT
Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer
CI
Antisense Therapeutics Appoints Gil Price as New Non-Executive Director
CI
Antisense Therapeutics Limited Announces Executive Changes
CI
Antisense Therapeutics Limited Announces Board Changes
CI
Antisense Therapeutics Limited Announces Executive Changes
CI
Antisense Therapeutics Limited Appoints Gil Price M.D. as Consultant Medical Director
CI
Antisense Therapeutics Limited Appoints Nuket Desem as Director of Clinical and Regulatory Affairs
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PER Stock
  4. News Percheron Therapeutics Limited
  5. Insiders